stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Shares outstanding
BioMarin Pharmaceutical Inc.'s shares outstanding at the end of fiscal 2025 was $197.4M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $193.6M. Over the past ten years it has ranged from $160.0M (fiscal 2015) to $197.4M (fiscal 2025) — the current reading is the highest in ten years. BioMarin Pharmaceutical Inc. ranks 52nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $197.4M | 0.35% |
| FY2024 | $196.7M | 2.67% |
| FY2023 | $191.6M | 1.39% |
| FY2022 | $189.0M | 3.34% |
| FY2021 | $182.9M | (4.60%) |
| FY2020 | $191.7M | 7.06% |
| FY2019 | $179.0M | 1.00% |
| FY2018 | $177.3M | 1.63% |
| FY2017 | $174.4M | 4.94% |
| FY2016 | $166.2M | 3.87% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $193.6M | (0.45%) |
| Jun 2026 | $194.5M | (1.62%) |
| Mar 2026 | $197.7M | 0.14% |
| Dec 2025 | $197.4M | 2.79% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| SMMT Summit Therapeutics PLC compare | $778.2M |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| BMRN BioMarin Pharmaceutical Inc. | $193.6M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| TECH Bio-Techne Corp compare | $157.0M |
| PCVX Vaxcyte, Inc. compare | $144.5M |
| KYMR Kymera Therapeutics, Inc. compare | $100.1M |
| TWST Twist Bioscience Corporation compare | $62.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement